Objective-Circulating human T effector memory cell (T EM ) recognition of nonself MHC (major histocompatibility complex) molecules on allograft endothelial cells can initiate graft rejection despite elimination of professional antigen-presenting cells necessary for naive T-cell activation. Our previous studies of CD4 T EM have established that engagement of the T-cell receptor not only activates T cells but also triggers transendothelial migration (TEM) by a process that is distinct from that induced by activating chemokine receptors on T cells, being slower, requiring microtubule-organizing center-directed cytolytic granule polarization to and release from the leading edge of the T cell, and requiring engagement of proteins of the endothelial cell lateral border recycling compartment. Although CD4 T EM may contribute to acute allograft rejection, the primary effectors are alloreactive CD8 T EM . Whether and how T-cell receptor engagement affects TEM of human CD8 T EM is unknown. Approach and Results-We modeled TEM of CD8 T EM across cultured human microvascular endothelial cells engineered to present superantigen under conditions of venular shear stress in vitro in a flow chamber. Here, we report that T-cell receptor engagement can also induce TEM of this population that similarly differs from chemokine receptor-driven TEM with regard to kinetics, morphological manifestations, and microtubule-organizing center dynamics as with CD4 T EM . However, CD8 T EM do not require either cytolytic granule release or interactions with proteins of the lateral border recycling compartment. Conclusions-These results imply that therapeutic strategies designed to inhibit T-cell receptor-driven recruitment based on targeting granule release or components of the lateral border recycling compartment will not affect CD8 T EM and are unlikely to block acute rejection in the clinic. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A llogeneic transplantation is the most effective treatment for many end-stage organ diseases. Facilitated by modern immunosuppressive regimens, acute allograft rejection rates have fallen dramatically but have not been completely eliminated. Unlike typical laboratory rodents, adult humans have a high frequency of alloreactive T effector memory cells (T EM ) in their circulation, and the pretransplant frequency of donorspecific memory T cells correlates with risk of acute rejection episodes. 1, 2 Allograft rejection by memory T cells can occur despite depletion of professional antigen-presenting cells from the graft 3 or a need to prime the host immune response in secondary lymphoid organs. 4, 5 Moreover, T EM are more difficult to suppress than naive T cells. 6, 7 Thus, it is important to understand how human T EM sense and are recruited to an allograft to further reduce rejection rates.
We have previously shown that human CD4 and CD8 T EM can be activated by direct recognition of allogeneic class II and class I MHC (major histocompatibility complex) molecule presentation, respectively, by cultured human endothelial cells (EC) 8 and that human EC may be rejected by adoptively transferred allogeneic T cells in vivo in immunodeficient mouse hosts. 9, 10 In vitro, EC presentation of antigen to CD4 T EM under conditions of flow not only causes T-cell activation but also induces transendothelial migration (TEM), a model of T-cell recruitment. 11 Remarkably, this process shares many more features of the interactions of a T cell with an antigen-presenting cell than it does with conventional chemotaxis or haptotaxis. Specifically, in response to T-cell receptor (TCR) engagement, CD4 T EM round up instead of flattening out and move their microtubule-organizing center (MTOC) and cytosolic granules to the region of contact with the EC rather than into a trailing uropod. Unexpectedly, degranulation proved to be a necessary step in the TEM process, apparently requiring extracellular granzyme A activity to successfully cross the EC monolayer. 12 TEM itself begins by pushing a thick cytoplasmic foot-like process that we have called a transendothelial protrusion (TEP), between adjacent EC. The nucleus then follows the MTOC into the TEP as TEM proceeds. 13 The transmigrating T cell engages the EC via LFA-1 binding to endothelial ICAM-1 (intercellular adhesion molecule-1) as well as interactions with EC proteins associated with the lateral border recycling compartment (LBRC) such as PECAM-1 (CD31), CD99, CD112, and CD155. 11, 14, 15 In contrast, chemokine-stimulated TEM of CD4 T EM may use either endothelial ICAM-1 or VCAM-1 (vascular cell adhesion molecule-1) and does not require interactions with proteins of the LBRC, degranulation, or extracellular granzyme A activity. Although CD4 T EM may contribute to rejection, the rejection process seems to correlate with the presence of CD8 cytotoxic T cells, 10 which may arise from CD8 T EM . 16 Recently, it has been demonstrated in mice that CD8 T cells can be recruited by antigen recognition on EC, triggering rejection independent of professional antigen-presenting cell. 17 Little is known about TEM by human CD8 T EM .
In the present study, we applied our in vitro flow chamber model that we previously used to analyze TEM by CD4 T EM to study the cell biology of human CD8 T EM recruitment in response to antigen and compare this both to chemokine responses of CD8 T EM and to our previous findings with CD4 T EM . Unexpectedly, we find significant differences between the TCR-mediated responses of these 2 populations.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
We modeled TEM of CD8 T EM across microvascular EC under conditions of venular shear stress in vitro in a flow chamber using tumor necrosis factor-activated, CIITA (class II transactivator)transduced monolayers of untransformed human dermal microvascular endothelial cells to present toxic shock syndrome toxin-1, a superantigen, to allogeneic T EM isolated from peripheral blood mononuclear cells. Toxic shock syndrome toxin-1 activates ≈5% to 10% of the T cells, namely, those clones that formed their TCR using a Vβ2 gene segment. This increases the frequency of responsive T cells to a level well above that activated by alloantigen (closer to 0.1%), significantly increasing the number of TCR-activated T cells available for analysis and allowing simultaneous analysis of both TCR-triggered Vβ2+ T EM and Vβ2-T EM responding to tumor necrosis factor-induced chemokines via chemokine receptors (CR) in the same field. 11 CIITA transduction is used to restore MHC class II expression lost by EC when placed in culture. Although MHC class II molecules are not required for allogeneic responses of CD8 T cells, they are necessary for the presentation of superantigen to both CD4 and CD8 T cells. Shear stress is required to stimulate the rapid TEM of T cells, whether the signal is antigen or chemokine. 11, 18, 19 Using this assay for CD8 T EM , we found this population to share many of the characteristics of CD4 T EM undergoing TEM. Shortly after encounter with superantigen, ZAP70 is phosphorylated at levels well above that induced by chemokines, indicative of TCR signaling. The extent of the phosphorylation varies from cell to cell, but the ranges completely overlap between the 2 populations, suggesting that signal strengths within these T-cell subsets are comparable ( Figure 1A ). In both cases, only the antigen-activated T EM become circular and rounded-up rather than spread and crawling. In Vβ2+ T cells, the MTOC then locates to a position between the T-cell nucleus and EC apical surface rather than trailing in the uropod, the latter being a shared feature of both CD4 and CD8 T EM in response to chemokine 12 ( Figure 1B ; Figure I in the online-only Data Supplement). By 15 minutes, TCR-activated cells start inserting TEPs between and under the EC. This is followed by transit of the nucleus through the monolayer, thereby completing TCR-driven TEM. As in CD4 T EM , TCR-driven TEM of CD8 T EM is delayed compared with CR-driven TEM 11 ( Figure 1C ). Treatment of T cells with blebbistatin, an inhibitor of myosin IIA, allows TEP formation but prevents cell body transit across the monolayer during TCR-driven TEM; blebbistatin has no effect on CR-driven TEM 13 ( Figure 1D ). As previously observed for CD4 T EM , 12 the MTOC, identified by staining for γ-tubulin, precedes the nucleus across the EC monolayer during CD8 TCR-driven TEM in stark contrast to CR-driven TEM, where the MTOC trails the nucleus ( Figure IA -IC in the online-only Data Supplement). Using NFAT (nuclear factor of activated T cells) translocation to the nucleus as a marker for T EM activated by alloantigen, we find that the MTOC similarly precedes the nucleus in alloantigen-driven TEM of both CD4 and CD8 T EM ( Figure 1E ).
Despite these similarities between the T-cell subsets, we also observed important differences between CD4 and CD8 T EM . Unlike CD4 T EM , the cytosolic granules of many (but not all) CD8 T EM , contain granzyme B as well as granzyme A and that when granzyme B is present, it colocalizes to the same granules as granzyme A ( [20] [21] [22] and Figure ID in the online-only Data Supplement). CD8 T EM granules also contain perforin, a necessary component for cytolysis, which is lacking in CD4 T EM ( 23 and data not shown). As we had seen with CD4 T EM , TCR signaling causes both the MTOC and cytosolic granules to be relocated to a region in proximity to the T cell-EC apical surface ( Figure I in the online-only Data Supplement). Unlike CD4 T EM , however, treatment with concanamycin A, an inhibitor of vesicular H + -ATPase on granules that thereby prevents acidification and renders them nonfunctional, failed to inhibit TCR-driven TEM of CD8 T EM Figure 2A ). In the presence of the serine protease inhibitor AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride), neither CR-nor TCR-driven TEM of CD8 T EM was inhibited, in contrast to TCR-driven TEM of CD4 T EM ( Figure 2B ). Furthermore, again in contrast to our previous studies of CD4 T EM 12 and experiments repeated here in parallel, quantification of granzyme A+ granules in T cells that receive TCR signals indicates that degranulation does not occur during TCR-driven TEM of CD8 T EM ( Figure 2C ). Interestingly, concanamycin A did inhibit CR-driven TEM of CD8, but not CD4 T EM , to a limited extent ( Figure 2A ). We next interrogated whether components of the LBRC were involved in TEM of CD8 T EM . Such interactions have been shown to be essential for human neutrophil and monocyte TEM. 24 Although our previous studies showed that CD4 T EM did not use LBRC proteins in response to chemokines, they did require their use when TEM was induced by TCR signals. 14, 15 Using approaches documented previously and repeated in parallel here, knockdown of PECAM-1 (CD31, knockdown confirmed by immunofluorescence staining) or blocking antibodies to CD112 and CD155 (on EC) or CD96 (on T cells) affected CD4 T EM TCR-driven TEM but had no effect on CD8 T EM TEM in response to chemokine or antigen ( Figure 3A-3C ). Furthermore, treatment of EC with an inhibitor of soluble adenylyl cyclase, an intracellular enzyme that facilitates leukocyte TEM by mobilizing vesicles of the LBRC to the plasma membrane, 25 selectively inhibited TCR-driven TEM of CD4 T EM ( Figure 3D ).
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We next examined the roles of other EC adhesion molecules in TEM, namely ICAM-1, VCAM-1, JAM-A, and JAM-B. TCR-driven TEM of both CD4 and CD8 T EM , as well as CR-driven TEM of CD8 T EM , showed a dependence on EC ICAM-1, as determined in experiments using ICAM-1 blocking monoclonal antibody (mAb) on the EC ( Figure 4A ) as well as knockdown of EC ICAM-1 by siRNA ( Figure 4B ; Treatment with a blocking mAb to integrin VLA-4 (α 4 subunit, CD49d), the known receptor for VCAM-1, selectively reduced CD4 T EM TCR-driven TEM, whereas blocking mAb to integrin LFA-1 (α L subunit, CD11a) and mAb to the common LFA-1 and Mac-1 β subunit (β 2 , CD18) effectively diminished both CD4 and CD8 T EM TCR-driven TEM ( Figure 5A through 5C). Because the mAb to LFA-1/Mac-1 seemed to be more potent than the mAb to LFA-1 in affecting CD8 T EM TCR-driven TEM, we also tested a blocking mAb to CD11b, the Mac-1 α subunit (α M ), but found no significant effect ( Figure 5D ). The blocking mAbs to LFA-1 and VLA-4 had similar effects on total T EM adhesion ( Figure 5E ). However, in contrast to CD4, CD8 T EM did not show an antigen-induced increase in binding, unless treated with an integrin-blocking mAb ( Figure 5F ).
Discussion
The fundamental points made by this study is that human CD8 T EM , like CD4 T EM , can be triggered to undergo a kinetically and morphologically distinct TEM process characterized by dramatic rearrangement of organelles to the leading edge of the cell, rather than to a trailing uropod, and an invasion between adjacent ECs led by a blunt TEP. Despite these similarities, CD4 and CD8 T EM TCR-driven TEM do differ in several important ways. Specifically, TCR-driven TEM of CD4 T EM requires granzyme A stored in cytolytic granules to be exocytosed to traverse the endothelium in a process that requires interactions with proteins of the LBRC, including PECAM-1, CD99, CD112, and CD155, with their receptors on the T cells. 12, 14, 15 Extracellular enzymatic activity of granzyme A is then required to permit TEM. The target of this serine protease is unknown, but it is possible that it may be needed to mobilize the LBRC to the plasma membrane. As shown here, CD8 T EM do not require either degranulation or engagement of endothelial proteins of the LBRC to transmigrate in response to TCR signals, although there is a small but significant effect of concanamycin A on CR-driven TEM of CD8 T EM . The limited effect of concanamycin on human CD8 T EM seems to contradict a previous report showing that granzyme B contributed to antigen-independent transmigration of differentiated CD8 CTL. 26 These differences likely reflect a difference between CD8 T EM , which are poised to become CTL, and functionally mature CTL. Only the latter degranulate in response to TCR signals. The modest effect of concanamycin A on CR-driven TEM of CD8 T EM that we observed could be explained by the presence of a relatively small subset of mature CTL in our freshly isolated peripheral blood human T EM subsets. Moreover, analysis of freshly isolated human CD8 T EM is likely to be complicated by the heterogeneity of subsets within this population; recent multiparameter phenotyping by CyTOF indicates that there are at least 4 subtypes of human Tc cells, and all lack expression of CCR7, like the T EM used here. 27 Nevertheless, the key point is that TCR-driven TEM of CD8 T EM does not seem to be affected by reagents that affect degranulation or TEM via the LBRC, as the same reagents effectively inhibit CD4 T EM in experiments performed in parallel. The exocytosis of granules seems to be a key difference between TCR-driven TEM of CD4 and CD8 T EM . It was recently shown that human memory CD4 T cells activated by antibodies for 24 hours will actually secrete more granzyme B than CD8 T cells, even though the percentage of granzyme B-containing CD4 T cells is much lower and CD8 T cells contain more intracellular granzyme B per cell. 28 Although this study compared freshly synthesized granzyme B in CD4 T cells to predominantly premade granzyme B in CD8 T cells, it nevertheless indicates that exocytosis of granules is under stricter control in memory CD8 T cells. With regard to transmigrating T cells, strict control of exocytosis in CD8 T EM makes sense teleologically because a relatively large number of CD8 T EM contain both granzymes A and B as well as perforin and would likely kill the EC if they were to degranulate during TEM. This would be a potentially disastrous consequence if CD8 T EM were being recruited to defend against a reinfection by an intracellular pathogen, the physiological role of this cell population. Interestingly, mature CTL will degranulate when encountering allogeneic EC, causing cell lysis, 16, 29 highlighting an important difference between CD8 CTL and CD8 T EM . The molecular explanation(s) for the differences in degranulation by CD4 and CD8 T EM are unknown, but experiments to determine this difference are an area of active investigation. One potential explanation could be a difference in the strength and/or duration of TCR signaling; it was recently shown that TCR-induced P-ZAP70 in mouse CD8 T cells is completely dephosphorylated within 30 minutes. 30 However, our assessment of the extent of ZAP70 phosphorylation suggests that the difference in degranulation between human CD4 and CD8 T EM interacting with antigen presented by EC cannot be explained by differences in the quantitative strength or duration of signaling.
It is interesting to speculate that the lack of degranulation of CD8 T EM during TCR-driven TEM and the lack of the need for interactions with proteins of the LBRC may be related. Other leukocyte cell types that use the LBRC for TEM are also dependent on serine proteases similar to granzyme A, for example, elastase 31 or proteinase 3. 32 Perhaps cleavage of an endothelial receptor by a serine protease is required to activate mobilization of the LBRC. With the exception of TCRdriven TEM by CD4 T EM , T cells seem to be independent of this mechanism. Perhaps LFA-1 engagement of EC ICAM-1 provides an alternative signal.
In contrast to our earlier results, 11 we now saw that VCAM-1-blocking Abs can selectively inhibit TCR-driven TEM of CD4 T EM . We attribute this discrepancy to the differences among anti-VCAM-1 antibodies. The mAb used in our previous report had a lower affinity than the 2 mAbs used here. We think the new finding to be correct both because we had similar effects by siRNA knockdown of VCAM-1 in EC and with use of a VLA-4-blocking mAb.
Although not the main focus of this study, we also found that, unlike CD8 T EM , CR-driven TEM of CD4 T EM cells is not inhibited by ICAM-1-blocking antibodies. The lack of effect of ICAM-1 blockade could imply either that ICAM-1 plays no role or that it is redundant in TEM of CR-driven CD4 T EM . Curiously, LFA-1-blocking Abs did have a small inhibitory effect on CR-driven TEM by CD4 T EM cells. This effect of LFA-1-blocking Abs is consistent with the inhibitory effects of JAM-A knockdown, because JAM-A is an alternative ligand for LFA-1. 33 Others have reported strong to modest effects of LFA-1-blocking Abs on TEM of freshly isolated human peripheral blood lymphocytes across cytokine-activated human umbilical vein ECs in static assays, with or without a chemotactic gradient [34] [35] [36] and ≈33% inhibition in flow assays with apically presented SDF-1α 18 ; in all cases, VLA-4blocking Abs had no effect on their own, but the combination of VLA-4 and LFA-1-blocking Abs was consistently potent. However, SDF-1α recruitment is not restricted to the T EM subset and other T-cell subsets may be more dependent on LFA-1 interactions. 19 Interestingly, effector T cells generated by TCR activation and prolonged culture in IL-2 are especially dependent on LFA-1 for TEM. 37 Not surprisingly, both LFA-1 and VLA-4-blocking Abs inhibited adhesion of CD4 and CD8 T EM cells; a limited number of experiments indicated that using both LFA-1 and VLA-4 antibodies have an additive effect. A curious observation is that the contribution of TCR signals to adhesion is different between CD4 and CD8 T EM . As noted previously 38 and replicated here, TCR signaling enhances adhesion of CD4 T EM , that is, the proportion of adherent T cells that are antigen specific is higher than the starting population. Such seems not to be the case for adhesion of CD8 T EM to EC, although an effect could be observed in the presence of integrin-blocking mAbs.
The differences between CD4 and CD8 T EM detailed here has significant clinical implications, particularly with regard to T cell-mediated graft rejection, a process dependent on the response of host T cells to the vascular endothelium of the allograft. 39 Blocking interactions of circulating T EM with proteins of the LBRC that might be effective in blocking recruitment of CD4 T EM may fail due to the independence of CD8 T EM recruitment of these target proteins. In contrast, agents that target common features, such as antibodies to LFA-1 or ICAM-1 can reduce TCR-driven TEM of both CD4 and CD8 T EM and, hence, inhibit graft rejection, but redundancy with VLA-4 (CD 49d/CD29) with VCAM-1 may still permit CR-induced recruitment. Experiments using humanized mice may help to address these questions as a complement to clinical trials.
